FindTrial
Sign In

YM178

DRUG11 trials

Sponsors

Astellas Pharma Inc, Astellas Pharma Europe B.V., Astellas Pharma China, Inc.

Conditions

Healthy Chinese VolunteersHealthy VolunteerOveractive BladderPharmacokineticsPharmacokinetics of YM178Renal ImpairmentUrinary Bladder, Overactive

Phase 1

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
CompletedNCT00750620
Astellas Pharma IncRenal Impairment
Start: 2008-09-30End: 2009-09-30Updated: 2013-09-05
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
CompletedNCT00856570
Astellas Pharma IncOveractive Bladder, Pharmacokinetics
Start: 2008-09-30End: 2008-12-31Updated: 2013-07-02
A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers
CompletedNCT00965926
Astellas Pharma IncHealthy Volunteer, Pharmacokinetics of YM178
Start: 2009-07-31End: 2009-09-30Updated: 2013-07-17
A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers
CompletedNCT01334905
Astellas Pharma IncHealthy Volunteer, Pharmacokinetics of YM178
Start: 2011-03-31End: 2011-06-30Updated: 2013-06-12
Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers
CompletedNCT01720212
Astellas Pharma China, Inc.Healthy Chinese Volunteers
Start: 2012-05-31End: 2012-08-31Updated: 2012-11-02

Phase 2

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
CompletedNCT00337090
Astellas Pharma IncOveractive Bladder
End: 2007-03-31Updated: 2013-07-02
A Study of YM178 in Patients With Symptomatic Overactive Bladder
CompletedNCT00527033
Astellas Pharma IncUrinary Bladder, Overactive
Start: 2007-09-11End: 2008-04-03Updated: 2024-10-31
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
CompletedNCT01604928
Astellas Pharma Europe B.V.Urinary Bladder, Overactive
Start: 2004-04-05End: 2005-01-25Updated: 2024-10-31

Phase 3

A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
CompletedNCT00840645
Astellas Pharma IncUrinary Bladder, Overactive
Start: 2008-12-31End: 2010-03-31Updated: 2016-01-05
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
CompletedNCT00966004
Astellas Pharma IncUrinary Bladder, Overactive
Start: 2009-07-24End: 2010-02-15Updated: 2024-10-31
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
CompletedNCT01043666
Astellas Pharma IncUrinary Bladder, Overactive
Start: 2009-12-21End: 2011-09-16Updated: 2024-10-31